Ascelia Pharma Ab Stock Profit Margin
| ACE Stock | SEK 3.14 0.01 0.32% |
Ascelia Pharma AB fundamentals help investors to digest information that contributes to Ascelia Pharma's financial success or failures. It also enables traders to predict the movement of Ascelia Stock. The fundamental analysis module provides a way to measure Ascelia Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ascelia Pharma stock.
Ascelia |
Ascelia Pharma AB Company Profit Margin Analysis
Ascelia Pharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Ascelia Pharma AB has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The profit margin for all Sweden stocks is 100.0% lower than that of the firm.
Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Ascelia Fundamentals
| Return On Equity | -0.54 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 359.6 M | |||
| Shares Outstanding | 33.67 M | |||
| Shares Owned By Insiders | 22.73 % | |||
| Shares Owned By Institutions | 31.16 % | |||
| Price To Book | 2.34 X | |||
| EBITDA | (129.45 M) | |||
| Net Income | (125.9 M) | |||
| Cash And Equivalents | 219.15 M | |||
| Cash Per Share | 9.69 X | |||
| Total Debt | 553 K | |||
| Current Ratio | 23.69 X | |||
| Book Value Per Share | 5.19 X | |||
| Cash Flow From Operations | (116.56 M) | |||
| Earnings Per Share | (3.67) X | |||
| Target Price | 65.0 | |||
| Number Of Employees | 21 | |||
| Beta | 0.89 | |||
| Market Capitalization | 483.48 M | |||
| Total Asset | 333.49 M | |||
| Net Asset | 333.49 M |
About Ascelia Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascelia Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascelia Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascelia Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ascelia Stock Analysis
When running Ascelia Pharma's price analysis, check to measure Ascelia Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascelia Pharma is operating at the current time. Most of Ascelia Pharma's value examination focuses on studying past and present price action to predict the probability of Ascelia Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascelia Pharma's price. Additionally, you may evaluate how the addition of Ascelia Pharma to your portfolios can decrease your overall portfolio volatility.